CDMO · ADC · Radiopharma · Cell and gene therapy · Built to order
CDMO capacity assessment: committed and schedulable capacity in fill-finish, biologics, ADC and radiopharma
How much CDMO capacity is genuinely schedulable in sterile fill-finish, biologics, ADC and radiopharma manufacturing, and who is crowding whom out.
What you receive
- A written report that answers the questions agreed at scoping, with a clear verdict on each
- The read from the leaders running these businesses, gathered through our search work and attributed by role
- A data workbook with the underlying tables, so your team can filter, check and reuse the work
- A source register with the source and date behind each key fact
What can be in scope
- Announced, committed and schedulable capacity by site and modality
- Crowd-out from large sponsors and from trade policy
- Tech transfer, qualification and release timelines
- Contract structures: reservation, take-or-pay, cancellation and transfer rights
- Supplier continuity and exit readiness
- Staffing behind each capacity state
Announced capacity and schedulable capacity are different numbers. A site can be built and still not be runnable: it may be waiting on qualification, short of people, or already committed to one large customer. This assessment separates what is announced, what is committed and what a sponsor could actually book.
It covers sterile fill-finish, biologics, ADC and radiopharma manufacturing, and is scoped to a provider, a target, a modality or a supply decision.
Who commissions it
- Investors diligencing a CDMO or a CDMO-dependent asset
- Sponsors securing fill-finish, biologics, ADC or radiopharma capacity
- Corporate development teams weighing build, buy or partner
- CDMO leadership teams reading competitors and customers
The questions it answers
- How much of a provider's or target's capacity is already committed, and to which kinds of customer?
- Which announced capacity is commercially schedulable, and which is still waiting on construction, qualification or staff?
- Where are large sponsors block-booking capacity, and which programmes get displaced?
- How long do tech transfer, qualification and release take at a given site, and what sits on the critical path?
- Can a programme move to another manufacturer if it needs to, and what does keeping that option cost?
- Which CDMO operating models hold their value, and which are exposed?
What you are buying access to
A proprietary intelligence base
Producers, facilities, pipelines, transactions, compensation and dated market signals across radiopharma, ADC, cell and gene therapy, CDMO and CRO, built and maintained by ProGen.
Access to the people who run it
Our executive search work puts us in conversation with the leaders of these businesses every week. Their read on the market goes into your answer.
Built around your decision
Scoped to the call in front of you: an investment, a partner, a supplier or a market. Every key fact sourced and dated.
How it works
Tell us your question
Choose an analysis below or describe your own. The more specific the decision, the sharper the scope.
Scope and quotation within one business day
We reply with the questions we will answer, what is in and out of scope, the timeline and a fixed quotation.
Your answer, built to stand up
A written report with a clear verdict, the read from the leaders in the space, a data workbook and a source register.
Request this analysis
Tell us the decision and the questions behind it. Within one business day you have the scope, the timeline and a fixed quotation.
Other analyses
- The Isotope Production MapEvery medical isotope producer, mapped by route and capacity. Refreshed quarterly.
- Ac-225 Supply and Demand OutlookWhen does Ac-225 stop being scarce, and who wins when it does?
- Isotope Supply Security AssessmentOne reactor, one target, one supplier. How exposed is your programme?
